par Crenier, Laurent 
Référence Revue médicale de Bruxelles, 43, 1, page (67-72)
Publication Publié, 2022-01-01
Référence Revue médicale de Bruxelles, 43, 1, page (67-72)
Publication Publié, 2022-01-01
Article révisé par les pairs
| Résumé : | Despite recent advances in the management of type 2 diabetes and the development of new therapeutic options, many patients still do not reach their glycemic targets. Until now, the most powerful anti-diabetic treatments were only available in injectables (insulin and GLP-1 receptor agonists, GLP-1 RA) and this may constitute a barrier to the treatment intensification in outpatient follow-up. In this context, the development of Rybelsus®, the first GLP-1 RA (semaglutide), available in tablets, is first and foremost a technological tour de force. But with a clinical efficacy and security comparable to that of its injectable equivalent, this newcomer to our therapeutic arsenal offers us a tremendous opportunity to improve the glycemic control of our type 2 diabetic patients in the first line of care. |
